Cargando…
Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
INTRODUCTION: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs, and the impact of tofacitinib on EIMs in pat...
Autores principales: | Rubin, David T., Reinisch, Walter, Greuter, Thomas, Kotze, Paulo G., Pinheiro, Marcia, Mundayat, Rajiv, Maller, Eric, Fellmann, Marc, Lawendy, Nervin, Modesto, Irene, Vavricka, Stephan R., Lichtenstein, Gary R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132089/ https://www.ncbi.nlm.nih.gov/pubmed/34035832 http://dx.doi.org/10.1177/17562848211005708 |
Ejemplares similares
-
The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme
por: Farraye, Francis A., et al.
Publicado: (2021) -
Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study
por: Vavricka, Stephan R., et al.
Publicado: (2022) -
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020) -
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021) -
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)